3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
56
Neoplasm Metastasis
4
Endometrial Neoplasms
4
Recurrence
3
Polycystic Ovary Syndrome
3
Ovarian Neoplasms
3
Neoplasms
2
Infertility
2
Carcinoma, Ductal, Breast
2
Breast Neoplasm Female
2
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Liposarcoma
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Carcinoma, Lobular
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Female
1
Anovulation
1
Advanced Breast Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
durvalumab
3
selpercatinib
2
palbociclib
2
Gonadotropin-Releasing Hormone
2
Cisplatin
2
Anastrozole
2
AZD9833
2
ribociclib
1
pembrolizumab
1
gallium 68 PSMA-11
1
ceralasertib
1
camrelizumab
1
anlotinib
1
abemaciclib
1
Taxes
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Pemetrexed
1
Paclitaxel
1
Nimorazole
1
Letrozole
1
Immunotherapy
1
Fulvestrant
1
CP protocol
1
Aspirin
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms by Site
×
Letrozole
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled